Skip to main content
. 2019 Aug;7(16):387. doi: 10.21037/atm.2019.07.43

Figure 5.

Figure 5

Survival analysis for patients with increases, no change, and decreases in CD8, PD-L1(T), PD-L1(L), CD20, and Foxp3.Survival analysis for patients with increases, no change, and decreases in (A) CD8, (B) PD-L1(T), (C) PD-L1(L), (D) CD20, and (E) Foxp3. PD-L1, programmed cell death ligand 1; PD-L1(T), PD-L1 in tumor cells; PD-L1(L), PD-L1 in lymphocytes.